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Objectives: To review community-level consumption of antibiotics in rural Vietnam, according to the WHO
Access, Watch, Reserve (AWaRe) classification of 2019, and identify factors associated with the choice of these
antibiotics.
Methods: In this cross-sectional study, data on antibiotic purchases were collected through a customer exit survey
of 20 community antibiotic suppliers in Ba Vi District, Hanoi, between September 2017 and July 2018. Antibiotic con-
sumption was estimated through the number of antibiotic encounters, the number of DDDs supplied and the
number of treatment days (DOTs) with antibiotics, and analysed according to the AWaRe classification. The factors
associated with watch-group antibiotic supply were identified through multivariable logistic regression analysis.
Results: In total, there were 1342 antibiotic encounters, with access-group antibiotics supplied in 792 encoun-
ters (59.0%), watch-group antibiotics supplied in 527 encounters (39.3%) and not-recommended antibiotics
supplied in 23 encounters (1.7%). No reserve-group antibiotics were supplied. In children, the consumption of
watch-group antibiotics dominated in all three measures (54.8% of encounters, 53.0% of DOTs and 53.6% of
DDDs). Factors associated with a higher likelihood of watch-group antibiotic supply were: private pharmacy (OR,
4.23; 95% CI, 2.8–6.38; P , 0.001), non-prescription antibiotic sale (OR, 2.62; 95% CI, 1.78–3.87; P , 0.001) and
children (OR, 2.56; 95% CI, 1.84–3.55; P , 0.001).
Conclusions: High consumption of watch-group antibiotics was observed, especially for use in children. The fre-
quent supply of watch-group antibiotics at private pharmacies reconfirms the need for implementing
pharmacy-targeted interventions in Vietnam.
Introduction
Overuse of antibiotics is a major public health issue.1,2 In the current
era of increasing antibiotic resistance and scarcity of new antibiotic
development, enhancing rational use of antibiotics is included as
one of five strategic objectives of the WHO global action plan on
antibiotic resistance, as well as the Vietnamese National Action
Plan.3–5 However, despite international efforts to regulate anti-
biotic use, the global consumption of antibiotics has continued
to increase over time.1,6–8 A recent study shows that global
antibiotic consumption increased by 65% between 2000 and
2015, primarily driven by low- and middle-income countries
(LMICs) that are experiencing economic growth. The total
amount of antibiotics consumed in LMICs, which was at a simi-
lar level to that in high-income countries (HICs) in 2000,
reached nearly 2.5 times that in HICs by 2015.9
In Vietnam, economic reforms during the 1980s and 1990s
helped transform the country from a low-income to a lower
middle-income country by 2013. This reform also led to an
increased number of private pharmacies and drug sellers, and un-
regulated access to antibiotics.10,11 Although laws exist to restrict
antibiotic use, the enforcement of these has remained insufficient.
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In addition, most antibiotic stewardship programmes have only
focused on hospitals, where resistant infections are identified,
while the vast majority of the antibiotics are consumed in the
community.12,13 These antibiotics are either prescribed by health-
care professionals or purchased directly by consumers without
prescription.14 In Vietnam, antibiotic self-medication through
private pharmacies is very common. According to a previous study,
88% of antibiotics dispensed in urban pharmacies and 91% in rural
pharmacies were without prescription. This practice was driven
by poor knowledge among pharmacy staff and customers on
antibiotics and resistance, as well as pharmacists’ fear of losing
customers, especially in rural areas.15
At the 21st meeting of the WHO Expert Committee on the
Selection and Use of Essential Medicines in 2017 the WHO Model List
of Essential Medicines (EML) and the Model List of Essential
Medicines for Children (EMLc) were reviewed and updated.16,17 An
important addition was a new categorization of antibacterials into
three groups, which emphasizes empiric treatment choices for com-
mon, community-acquired infections that are broadly applicable in
the majority of countries. The WHO recommended use of this classi-
fication to assist in the development of antibiotic stewardship
at local, national and global levels. In October 2019, this classifica-
tion was updated and reformed as a classification database.
Accordingly, 180 common antibacterials are classified into three
groups: access, watch or reserve (AWaRe). Access-group antibiotics
include 49 antibiotics that have activity against a wide range of com-
monly encountered susceptible pathogens and a lower resistance
potential than antibiotics in the other groups. Watch-group antibiot-
ics include 110 antibiotics that have higher resistance potential.
Finally, 22 reserve-group antibiotics should be considered antibiotics
of last resort, which should be tailored to highly specific patients
and settings, when all alternatives have failed or are not suitable.
The database also lists those antibiotics whose use is not recom-
mended by WHO, namely fixed-dose combinations of multiple
broad-spectrum antibiotics that lack evidence-based indications
for use or recommendations in high-quality international guidelines.
This classification has been used in several antibiotic-use studies
to review the current levels of the use of watch- and reserve-group
antibiotics in different settings.18,19 However, a limitation of these
studies is the inclusion of hospital antibiotic consumption data,
which also included hospital-acquired infections, while the WHO
EML primarily focuses on antibacterial choices for common,
community-acquired infections. Furthermore, the use of integrated
antibiotic sales data means that individual-level factors associated
with the use of different groups of antibiotics could not be explored.
Lastly, as the classification was changed in October 2019, after pub-
lication of these data, they still use the old classification.
Therefore, we conducted this study to assess community-level
antibiotic consumption according to the WHO AWaRe groups and
to identify the factors associated with the choice of watch-
and reserve-group antibiotics in a rural area in Vietnam, an LMIC in
Southeast Asia.
Methods
Study design and setting
This cross-sectional study was part of the ABACUS (AntiBiotic Access and
Use) study.20 The primary objective of ABACUS was to identify targets for
community-based, tailored intervention strategies to promote appropriate
antibiotic use across communities in six LMICs in Asia (Bangladesh,
Thailand and Vietnam) and Africa (Mozambique, Ghana and South Africa).
For each study site, including Vietnam, all possible antibiotic dispensing
points (antibiotic suppliers) were mapped and were eligible to participate in
this study. This included any formal or informal antibiotic supplier in the
community, from public hospital pharmacy to street vendor.
Our study used data collected through face-to-face customer exit sur-
veys at 20 antibiotic suppliers, between September 2017 and July 2018, in
Ba Vi District, located 60 km west of the centre of Hanoi, Vietnam. It covers
410 km2 and has a population of 274 000 people within 31 communes. The
healthcare system includes a district hospital with 300 beds, 3 public poly-
clinics and 31 commune health stations and village health workers, as well
as private facilities and pharmacies.21 Private pharmacies have been shown
to be the most accessible and accessed drug-selling points in this area.15
Study participants
In Ba Vi District, 20 of 502 antibiotic suppliers were selected for customer
exit interviews. The selection was based on highest rank in number of daily
antibiotic encounters. Four suppliers refused to participate in the survey at
our first invitation and were replaced by four other suppliers. The final
selected suppliers included 5 drug outlets in public health settings (1 from a
district hospital, 1 from a local polyclinic and 3 from commune health sta-
tions) and 15 private pharmacies. To limit biases caused by seasonal varia-
tions, the survey was performed four times over a 1 year period between
September 2017 and July 2018. We selected 30 encounters per supplier
from 20 suppliers to represent the study population, based on WHO and
International Network for Rational Use of Drugs (WHO/INRUD)
methodology.22
At the selected suppliers, each customer who left the pharmacy during
one of the four 3 day data collection phases was approached and asked
whether antibiotics had been supplied to them. In the case of an antibiotic
encounter, the customer was asked to participate in the customer exit
interview. To be included in the study, customers had to be willing to dis-
close whether antibiotics were supplied to them and consent to participate
in an interview. Recruitment of participants was stopped when either the
end of that survey round was reached or 30 customers with antibiotic
encounters were recruited.
Data collection and management
Demographics of antibiotic purchasers, antibiotic supply (name, dosage,
number of units supplied and length of treatment) and self-reported health
conditions for requesting antibiotics (health problems or symptoms) were
collected from antibiotic purchasers through face-to-face interviews using
a structured questionnaire (Appendix S1, available as Supplementary data
at JAC-AMR Online). Antibiotic purchases for children were defined accord-
ing to the respondent’s report, with no pre-specified age range. All of the
interviews were conducted by field workers of the FilaBavi Health
Demographic and Surveillance Site, who had previous experience in data
collection and were trained on the content of the questionnaire as well as
interview skills. The REDCap data management platform (redcap.core.wit-
s.ac.za) was used for data collection.
Data analysis
We presented antibiotic consumption in three measures: antibiotic encoun-
ters, DDDs and days of treatment (DOTs). For each antibiotic encounter, the
number of DDDs was measured through the number of standard units sup-
plied, the strength of antibiotic products and the DDD assigned for each
drug by the WHO Collaborating Centre and the WHO International Working
Group on Drug Statistics Methodology. In this study, we applied the DDD for
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created. For DOT measurement, the number of DOTs was defined according
to the respondent’s report.
The patterns of use were described according to the 2019 WHO AWaRe
antibiotic classification, in which antibiotics were classified into four
groups: access, watch, reserve and not recommended.16 For encounters
with a combination of antibiotics, the classification of the encounter
would be based on the higher restricted antibiotic. For instance, if the cus-
tomer’s basket contained both watch-group and access-group antibiotics,
the encounter would be classified as a watch-group antibiotic encounter.
We also used the WHO Anatomical Therapeutic Chemical (WHO ATC)
classification to rank the consumption of pharmacological classes of
antibiotics.
We performed multivariable logistic regression analysis to review the
factors associated with the choice of watch- and reserve-group antibiotics
because both of them are recommended by WHO as key targets of anti-
biotic stewardship programmes and monitoring.16,17 Since the use of
reserve-group antibiotics was not observed in our study population (see the
Results section), our analysis only reviewed the factors associated with the
choice of watch-group antibiotics.
R version 3.5.1 was used for all data analyses.
Ethics
The study protocol was reviewed by the Oxford University Tropical Research
Ethics Committee (OxTREC, Reference: 31-15) and the National Vietnamese
ethical committees [Vietnam Ministry of Health (MoH) Institutional Review
Board (IRB) (6670/QD-BYT)] and the Ethical Committee of Hanoi Medical
University (No. 195/HMU IRB).
Results
A total of 1404 antibiotic encounters were included in this study,
of which 1342 antibiotic encounters were related to human
use. Customers’ characteristics from these 1342 antibiotic
encounters are presented in Table 1. Customers’ median age
was 40 years (IQR: 30–55) and 69.0% were female. In 389
encounters (28.9%), antibiotics were purchased for children.
Antibiotics were purchased without prescription in 773 encoun-
ters (57.6%). Cough (724 cases, 53.9%), sore throat (644 cases,
48.0%), fever (447 cases, 33.3%) and runny nose (378 cases,
28.2%) were the most common health problems and symp-
toms for purchasing antibiotics.
Table 2 shows consumption levels of access-, watch- and
reserve-group antibiotics, estimated by the number of antibiotic
encounters, the number of DOTs and the number of DDDs supplied.
In the total of 1342 antibiotic encounters, access-group antibiotics
were provided in 792 encounters (59.0%), watch-group antibiotics
in 527 encounters (39.3%) and not-recommended antibiotics in
23 encounters (1.7%). The total DOTs with antibiotics was 5889, of
which 3484 (59.2%) were access-group, 2293 (38.9%) were
watch-group and 112 (1.9%) were not-recommended antibiotics.
The total DDDs dispensed was 7221.7 DDDs, of which 3663.8
(50.7%) were access-group, 3414.1 (47.3%) were watch-group
and 143.8 (2.0%) were not-recommended antibiotics. There were
no reserve group antibiotics dispensed among the interviewees. In
children, the consumption of watch-group antibiotics was the
highest according to all three measures: number of encounters
(54.8%), number of DOTs (53.0%) and number of DDDs (53.6%).
In addition to comparing antibiotic consumption by WHO
AWaRE antibiotic groups, we performed an analysis of the con-
sumption of different chemical classes of antibiotics (according to
the 4th level WHO ATC classification) (Table 3). The five most con-
sumed antibiotic groups accounted for more than 80% of total
consumption. These included two from the access group: penicil-
lins with extended spectrum [380 encounters (28.3%), 1865.8
DDDs (25.8%) and 1531.5 DOTs (26.0%)] and first-generation
cephalosporins [305 encounters (22.7%), 1282.8 DDDs (17.8%)
and 1349 DOTs (22.9%)]; and three from the watch group: third-
generation cephalosporins [161 encounters (12%), 852.6 DDDs
(11.8%) and 745 DOTs (12.6%)], macrolides [159 encounters
(11.8%), 944.5 DDDs (13.1%) and 700 DOTs (11.9%)]; and second-
generation cephalosporins [135 encounters (10.0%), 1147 DDDs
(15.9%) and 626.5 DOTs (10.6%)].
Since the use of reserve-group antibiotics was not observed in
our study population, the multivariate analysis focused on the fac-
tors associated with watch-group antibiotic supply. Our analysis
shows that non-prescription sales of antibiotics (OR, 2.62; 95% CI,
1.78–3.87; P , 0.001), antibiotic purchase for children (OR, 2.56;
95% CI, 1.84–3.55, P , 0.001), private pharmacies (OR, 4.23; 95%
CI, 2.8–6.83; P , 0.001), dental symptoms (OR, 3.17; 95% CI, 1.47–
6.87; P"0.003) and urinary tract symptoms (OR, 3.46; 95% CI,
1.6–7.46; P , 0.001) were associated with a more frequent supply
of watch-group antibiotics (Figure 1). For the populations carrying
these factors, the use of different watch-group antibiotics was
described in Table S1.





age, median (IQR) (years) 40 (30–55)
female gender 926 69.0
antibiotic purchase for children 389 28.9
non-prescription sale of antibiotics 773 57.6
private pharmacies 863 64.3
Reason for purchasing antibiotics
chest pain 66 4.9
cough 724 53.9
dental symptoms 37 2.8
dyspnoea 71 5.3
ear and eye symptoms 36 2.7
fever 447 33.3
gastrointestinal symptoms 125 9.3
gynaecological symptoms 23 1.7
headache 162 12.1
musculoskeletal symptoms 16 1.2
runny nose 378 28.2
skin and soft tissue symptoms 28 2.1
surgery-related symptoms 4 0.3
sore throat 644 48.0




















Our study shows that access-group antibiotics such as extended-
spectrum penicillins (e.g. amoxicillin and ampicillin) and first-
generation cephalosporins (e.g. cefalexin) were the most frequent-
ly purchased in a rural community in Vietnam, comprising nearly
60% of total antibiotic use by all three measures. This is similar
to what was observed in a previous study, in which the three
most commonly sold antibiotics in rural pharmacies in Vietnam
were amoxicillin (27%), cefalexin (20%) and ampicillin (12%).15
Although these agents are recommended by WHO as first-line
treatments for common community-acquired infections, it should
be noted that antibiotics should be provided only if there is high
suspicion of bacterial involvement.16,23 In this study, the majority
of antibiotics were supplied without prescription to patients
with respiratory tract symptoms, which have been proven to be
viral in the majority of cases. In addition, for a large proportion
of bacterial respiratory tract infections such as bronchitis, otitis
media, sinusitis and sore throat, antibiotic treatment is not
recommended.24
Around 40% of customers in our study population were treated
with watch-group antibiotics, including oral second- and third-
generation cephalosporins (cefuroxime, cefixime, cefdinir and cef-
podoxime), macrolides (azithromycin, clarithromycin and erythro-
mycin) and fluoroquinolones (levofloxacin and ciprofloxacin).
Because of higher resistance potential, the use of watch-group
antibiotics is only recommended as first- or second-choice treat-
ments for a limited number of indications.16 The overuse of oral
cephalosporins, especially cefuroxime and cefixime, can disrupt
the intestinal microbiome, select for resistant organisms and is
associated with a significant increased risk of Clostridioides difficile
infection.25,26 For macrolides, the increased use of these agents in
recent years has been shown to be linked to increased macrolide
resistance in Streptococcus pneumoniae, especially in Asian
countries.27,28 In Taiwan, among 276 isolates of S. pneumoniae
collected from five major teaching hospitals, the rate of macrolide-
resistant S. pneumoniae was over 90%.29 Fluoroquinolones are
highly effective antibiotics for respiratory and urinary tract infec-
tions. However, the susceptibility of the pathogens causing these
infections to fluoroquinolones has rapidly dropped in Asia-Pacific
regions, especially in antimicrobial resistance hotspots such as
Vietnam or China.30–32 Our subgroup analyses also increase con-
cerns regarding inappropriate use of antibiotics in the community
(Table S1). In this study, 50% of dental symptoms were treated
with macrolides (mainly spiramycin/metronidazole) while amoxi-
cillin and amoxicillin/clavulanic acid are recommended as first-line
treatments in oral and dental infections.33 Similarly, nearly 60% of
urinary tract symptoms were treated with fluoroquinolones while
first-line treatments recommended for community-acquired
non-complicated urinary tract infections are narrow-spectrum
antibiotics such as trimethoprim and nitrofurantoin.14 The
observation that no reserved-group antibiotic encounters were
observed in this study could be explained by the fact that all of
these agents are parenteral drugs, which are rarely available in
rural pharmacies. However, reporting this information is import-
ant to provide a reference for similar studies in urban pharmacies
in the future. In these areas, community pharmacies near big
hospitals can sell parenteral antibiotics for patients whose indica-
tions are not reimbursed by the National Health Reimbursement
Agency.
Another important finding of this study is the significantly
higher proportion of use of watch-group antibiotics for children
(nearly 55% in all three measures), confirmed to increase the likeli-
hood of watch-group antibiotic supply in our multivariate analysis.
This proportion is higher than observed in a study by Hsia et al.18
(43.1%). In this study, antibiotic sales data for children from 70
countries were ranked and Vietnam ranked fifth for consumption
of watch-group antibiotics. Excessive consumption of antibiotics in
children has been seen in many countries, including HICs. In South
Korea, children younger than 10 years were the population most
frequently treated with antibiotics.34 In the USA, outpatient and
community-level use of broad-spectrum antibiotics in children
was observed to steadily increase over time.35,36 There are several
hypotheses for the overconsumption of watch-group antibiotics
in our child population. Firstly, because of poor understanding of
antibiotic use and resistance, parents often ask for newer and
more expensive antibiotics, which are commonly broad-spectrum
antibiotics, to treat their children. Secondly, because parents often
visit pharmacies, explain their child’s symptoms and ask for
Table 2. Antibiotic consumption according to WHO AWaRe antibiotic
groups, estimated by antibiotic encounters, DDDs and DOTs
Total Adults Children




792 59.0 625 65.6 167 42.9
watch-group
antibiotics
527 39.3 314 32.9 213 54.8
reserve-group
antibiotics
0 0 0 0 0 0
not-recommended
antibiotics
23 1.7 14 1.5 9 2.3




3484 59.2 2722.5 65.3 761.5 44.3
watch-group
antibiotics
2293 38.9 1383 33.2 910 53.0
reserve-group
antibiotics
0 0 0 0 0 0
not-recommended
antibiotics
112 1.9 65 1.6 47 2.7




3663.8 50.7 2927.5 52.9 736.3 43.6
watch-group
antibiotics
3414.1 47.3 2508.9 45.3 905.2 53.6
reserve-group
antibiotics
0 0 0 0 0 0
not-recommended
antibiotics
143.8 2.0 97.1 1.8 46.7 2.8
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Table 3. The proportional consumption (% of total consumption) of the WHO ATC chemical classes of antibiotics




antibiotic encounters number of DOTs number of DDDs
n % n % n %
J01CA penicillins with extended spectrum access 380 28.3 1531.5 26.0 1865.8 25.8
J01DB first-generation cephalosporins access 305 22.7 1349.5 22.9 1282.8 17.8
J01DD third-generation cephalosporins watch 161 12.0 745 12.6 852.6 11.8
J01EE macrolides watch 159 11.8 700 11.9 944.5 13.1
J01DC second-generation cephalosporins watch 135 10.0 626.5 10.6 1147 15.9




58 4.3 269.5 4.6 295.1 4.1
J01MA fluoroquinolones watch 37 2.8 183 3.1 322 4.5
J01EE combinations of sulphonamides and tri-
methoprim, including derivatives
access 35 2.6 164.5 2.8 191.3 2.6
J01FF lincosamides access 34 2.5 166 2.8 162.3 2.2
J01AA tetracyclines access 14 1.0 51.5 0.9 93.5 1.3
J01BA amphenicols access 19 1.4 80 1.4 25.1 0.3
J01CE b-lactamase-sensitive penicillins access 5 0.4 19.5 0.3 10.4 0.1
J01XD imidazole derivatives access 1 0.1 10 0.2 28.3 0.4
J01GB other aminoglycosides (aminoglycosides
other than streptomycin)
access 1 0.1 1 0.0 1 0.0
 Adjusted OR (95% CI) 
Factors Adjusted OR (95% CI) P value
Age 1.00 (0.99–1.00) 0.480 
Gender (female) 1.02 (0.78–1.34) 0.862 
Non-prescription sales  2.62 (1.78–3.87) <0.001 
Children  2.56 (1.84–3.55) <0.001 
Pharmacy 4.23 (2.80–6.83) <0.001 
Chest pain 0.85 (0.47 -1.55) 0.596 
Cough 1.09 (0.80 -1.47) 0.599 
Dental symptoms 3.17 (1.47–6.87) 0.003 
Dyspnoea 1.41 (0.80–2.49) 0.228 
Ear and eye symptoms 1.25 (0.58–2.69) 0.571 
Fever 0.76 (0.56–1.02) 0.066 
Gastrointestinal symptoms 0.50 (0.29–0.86) 0.013 
Gynaecological symptoms 0.81 (0.30–2.24) 0.690 
Headache 0.73 (0.48–1.13) 0.157 
Musculoskeletal symptoms 0.63 (0.17–2.34) 0.489 
Running nose 1.00 (0.74–1.36) 0.983 
Skin and soft tissue symptoms 1.68 (0.73–3.85) 0.224 
Surgery-related symptoms 2.28 (0.28–18.42) 0.439 
Sore throat 1.18 (0.89–1.56) 0.262 
Urinary tract symptoms 3.46 (1.6–7.46) 0.002 
Wound 
0 1 2 3 4 5 6 7 8
0.95 (0.49–1.86) 0.882 
Figure 1. Results from multiple logistic regression analysis modelling the associations between watch-group antibiotic supply and baseline
covariates.
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medications without bringing the children with them, pharmacists
might tend to choose broad-spectrum antibiotics to cover most
bacterial infections. Thirdly, selling broad-spectrum antibiotics is
often more profitable for antibiotic suppliers than selling narrow-
spectrum antibiotics. Broad-spectrum antibiotics (e.g. azithromy-
cin or cefixime) are often more expensive and less common com-
pared with narrow-spectrum antibiotics (e.g. ampicillin). It is easier
for suppliers to set higher retail prices for these, since parents have
fewer sources for price reference and are always willing to pay
higher costs for their children. Although these hypotheses need
to be confirmed in future studies, restricting the supply of broad-
spectrum antibiotics to children is crucial. In fact, the use of broad-
spectrum antibiotics to treat common bacterial infections in
children was shown to have no more clinical benefit and cause
more adverse effects than narrow-spectrum antibiotics.37
More importantly, using these antibiotics in the early stages of life
was proven to be among the key drivers of antimicrobial resistance
and therefore could lead to poor efficacy of antibiotics in the
future.38
Although antibiotic supply without valid prescription is illegal in
Vietnam, more than 90% of antibiotic dispensations in private
pharmacies in rural areas were without prescription.15 In this
study, private pharmacies also had a higher proportion of dispens-
ing watch-group antibiotics. This could be explained by differences
in business models between private pharmacies and other com-
munity antibiotic suppliers (drug outlets inside public hospitals,
polyclinics or commune health centres). These latter suppliers
mainly provide prescribed antibiotics under the national health in-
surance programme, while private pharmacies exist by gaining
profits from selling medications to cash customers.10 Therefore,
the pursuit of profit might incentivize community pharmacists to
sell more expensive antibiotics to customers, with less regard for
appropriateness.10,15,21,32,39 In a previous survey with pharmacists
in rural Vietnam, nearly 80% of respondents confirmed that per-
ceived customer pressure and fear of losing customers leads to
irrational antibiotic dispensation.15 This is similar to what was
observed in India, Ethiopia and Tanzania, where refusal to dis-
pense antibiotics was seen to possibly affect the sales of pharma-
cies.14 To tackle this issue, the law prohibiting over-the-counter
sales of antibiotics needs to be more effectively enforced. In add-
ition, other pharmacy-targeted interventions to enhance rational
access and use of antibiotics should be developed. In the UK, the
use of point-of-care tests in pharmacies to guide treatment deci-
sions was shown to reduce unnecessary antibiotic use in a rural
community.40 However, there is still a lack of evidence on the feasi-
bility and applicability of these tests in community pharmacies in
LMICs.
This study has several strengths. First, to our knowledge, this is
among the first studies applying the 2019 WHO AWaRe classifica-
tion in an analysis of antibiotic consumption in an LMIC. Compared
with the 2017 classification, this updated version expanded the
classification to cover non-essential antibiotics. Therefore, this
minimizes the frequency of unclassified antibiotics in our study,
which was commonly seen in previous studies.18,19 Second, in this
study, antibiotic consumption was measured by different metrics
(either the number of antibiotic encounters, the number of DDDs
or the number of DOTs) to see how our study conclusions varied
when the estimation method was changed. Third, the combined
data on antibiotic consumption with patient-level factors allowed
an exploration of risk factors for inappropriate antibiotic use.
Fourth, because the data collection was conducted immediately
after sales, the impact of recall bias on information about antibiotic
type and dose was minimized. Finally, by using experienced inter-
viewers who work in a demographic surveillance site, the quality of
the data collected was ensured.
This study is limited by the fact that it was conducted in only
the 20 largest antibiotic suppliers in one rural district. Therefore,
our results may not be representative of smaller suppliers, urban
communities or other parts of Vietnam. In addition, the frequency
of watch-group antibiotics dispensed by large suppliers may be
higher because their customers may have more severe health
issues than customers of small suppliers. Our small sample size
(1342), compared with the expected sample size (2400), also
affects the generalizability of this study (see Table S2 for accom-
plishment rate of recruitment in each supplier). The fact that four
suppliers refused to participate in the survey at our first invitation
and were replaced by other suppliers might be related to their anti-
biotic supply practices and also affect generalizability. Finally, each
estimation measure used in this study only gives a rough estimate
of antibiotic consumption. The accuracy of DOT data could be
affected by recall bias and using adult DDDs to estimate consump-
tion in children could lead to underestimation of actual consump-
tion in children. Therefore, we presented consumption data by
both number of encounters, DOTs and DDDs to see whether there
was good agreement between different estimates. This approach
was used in previous studies.41,42
In conclusion, although access-group antibiotics were the
most commonly used antibiotics in community pharmacies in a
rural area in Vietnam, the consumption level of watch-group
antibiotics is remarkably high, especially among children. The
factors significantly associated with a higher chance of supply-
ing watch-group antibiotics were private pharmacy, non-
prescription antibiotic supply and antibiotic sales for children.
These findings elaborate earlier reports and confirm existing
concerns regarding inappropriate antibiotic dispensing in
rural Vietnam, which may be similar in other LMICs. There is an
urgent need for pharmacy-targeted interventions to tackle this
problem.
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